Santhera Pharmaceuticals Holding Stock Net Income
| SANN Stock | CHF 16.90 0.40 2.42% |
As of the 27th of February, Santhera Pharmaceuticals has the Semi Deviation of 2.08, coefficient of variation of 504.53, and Risk Adjusted Performance of 0.1588. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santhera Pharmaceuticals, as well as the relationship between them. Please validate Santhera Pharmaceuticals information ratio, treynor ratio, value at risk, as well as the relationship between the jensen alpha and maximum drawdown to decide if Santhera Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 16.9 per share.
Santhera Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.3238 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -37.8 M | -39.7 M | |
| Net Loss | -37.8 M | -39.7 M | |
| Net Loss | -37.8 M | -39.7 M | |
| Net Loss | (3.32) | (3.49) | |
| Net Income Per E B T | 0.91 | 0.76 |
Santhera | Net Income |
The evolution of Net Income for Santhera Pharmaceuticals Holding provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Santhera Pharmaceuticals compares to historical norms and industry peers.
Latest Santhera Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Santhera Pharmaceuticals Holding over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Santhera Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Santhera Pharmaceuticals Holding operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Santhera Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Santhera Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (41.97 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Santhera Net Income Regression Statistics
| Arithmetic Mean | (30,228,531) | |
| Coefficient Of Variation | (100.73) | |
| Mean Deviation | 21,643,849 | |
| Median | (35,415,000) | |
| Standard Deviation | 30,450,340 | |
| Sample Variance | 927.2T | |
| Range | 125.9M | |
| R-Value | (0.16) | |
| Mean Square Error | 964T | |
| R-Squared | 0.03 | |
| Significance | 0.54 | |
| Slope | (960,350) | |
| Total Sum of Squares | 14835.6T |
Santhera Net Income History
Santhera Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Santhera Pharmaceuticals is extremely important. It helps to project a fair market value of Santhera Stock properly, considering its historical fundamentals such as Net Income. Since Santhera Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Santhera Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Santhera Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Santhera Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Santhera Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Santhera Pharmaceuticals.
| 11/29/2025 |
| 02/27/2026 |
If you would invest 0.00 in Santhera Pharmaceuticals on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding Santhera Pharmaceuticals Holding or generate 0.0% return on investment in Santhera Pharmaceuticals over 90 days. Santhera Pharmaceuticals is related to or competes with Alcon AG, Sandoz Group, Straumann Holding, Ypsomed Holding, Sonova H, SKAN Group, and Tecan Group. Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and co... More
Santhera Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Santhera Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Santhera Pharmaceuticals Holding upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.5 | |||
| Information Ratio | 0.1638 | |||
| Maximum Drawdown | 18.95 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 7.25 |
Santhera Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Santhera Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Santhera Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Santhera Pharmaceuticals historical prices to predict the future Santhera Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1588 | |||
| Jensen Alpha | 0.6596 | |||
| Total Risk Alpha | 0.1708 | |||
| Sortino Ratio | 0.2333 | |||
| Treynor Ratio | 2.24 |
Santhera Pharmaceuticals February 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1588 | |||
| Market Risk Adjusted Performance | 2.25 | |||
| Mean Deviation | 2.58 | |||
| Semi Deviation | 2.08 | |||
| Downside Deviation | 2.5 | |||
| Coefficient Of Variation | 504.53 | |||
| Standard Deviation | 3.55 | |||
| Variance | 12.63 | |||
| Information Ratio | 0.1638 | |||
| Jensen Alpha | 0.6596 | |||
| Total Risk Alpha | 0.1708 | |||
| Sortino Ratio | 0.2333 | |||
| Treynor Ratio | 2.24 | |||
| Maximum Drawdown | 18.95 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 7.25 | |||
| Downside Variance | 6.23 | |||
| Semi Variance | 4.34 | |||
| Expected Short fall | (3.31) | |||
| Skewness | 1.23 | |||
| Kurtosis | 2.66 |
Santhera Pharmaceuticals Backtested Returns
Santhera Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Santhera Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.19, which indicates the firm had a 0.19 % return per unit of risk over the last 3 months. By inspecting Santhera Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.62% is justified by implied risk. Please review Santhera Pharmaceuticals' Coefficient Of Variation of 504.53, semi deviation of 2.08, and Risk Adjusted Performance of 0.1588 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Santhera Pharmaceuticals holds a performance score of 14. The entity has a beta of 0.31, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Santhera Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Santhera Pharmaceuticals is expected to be smaller as well. Please check Santhera Pharmaceuticals' total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to make a quick decision on whether Santhera Pharmaceuticals' existing price patterns will revert.
Auto-correlation | 0.79 |
Good predictability
Santhera Pharmaceuticals Holding has good predictability. Overlapping area represents the amount of predictability between Santhera Pharmaceuticals time series from 29th of November 2025 to 13th of January 2026 and 13th of January 2026 to 27th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Santhera Pharmaceuticals price movement. The serial correlation of 0.79 indicates that around 79.0% of current Santhera Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.79 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 1.94 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Santhera Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Santhera Pharmaceuticals Holding reported net income of (41.97 Million). This is 112.3% lower than that of the Biotechnology sector and 159.92% lower than that of the Health Care industry. The net income for all Switzerland stocks is 107.35% higher than that of the company.
Santhera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in net income category among its peers.
Santhera Fundamentals
| Return On Equity | -2.88 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.34) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 162.92 M | ||||
| Shares Outstanding | 13.39 M | ||||
| Shares Owned By Insiders | 15.14 % | ||||
| Shares Owned By Institutions | 4.74 % | ||||
| Price To Earning | (7.01) X | ||||
| Price To Book | 6.56 X | ||||
| Price To Sales | 4.70 X | ||||
| Revenue | 39.12 M | ||||
| Gross Profit | 6.57 M | ||||
| EBITDA | (15.89 M) | ||||
| Net Income | (41.97 M) | ||||
| Cash And Equivalents | 22.59 M | ||||
| Cash Per Share | 2.07 X | ||||
| Total Debt | 41.17 M | ||||
| Debt To Equity | 196.00 % | ||||
| Current Ratio | 2.19 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (35.53 M) | ||||
| Earnings Per Share | (5.38) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 78 | ||||
| Beta | -0.74 | ||||
| Market Capitalization | 142.15 M | ||||
| Total Asset | 152.49 M | ||||
| Retained Earnings | (614.69 M) | ||||
| Working Capital | 29.67 M | ||||
| Net Asset | 152.49 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.